NO20030474L - Legemiddel mot demens inneholdende 2-aryl-8- oksodihydropurinderivater som aktiv bestanddel - Google Patents

Legemiddel mot demens inneholdende 2-aryl-8- oksodihydropurinderivater som aktiv bestanddel

Info

Publication number
NO20030474L
NO20030474L NO20030474A NO20030474A NO20030474L NO 20030474 L NO20030474 L NO 20030474L NO 20030474 A NO20030474 A NO 20030474A NO 20030474 A NO20030474 A NO 20030474A NO 20030474 L NO20030474 L NO 20030474L
Authority
NO
Norway
Prior art keywords
aryl
active ingredient
drug containing
dementia drug
oxodihydropurine derivatives
Prior art date
Application number
NO20030474A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030474D0 (no
Inventor
Kiyoshi Furukawa
Satoshi Kurumiya
Takashi Hashimoto
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of NO20030474D0 publication Critical patent/NO20030474D0/no
Publication of NO20030474L publication Critical patent/NO20030474L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20030474A 2000-07-31 2003-01-30 Legemiddel mot demens inneholdende 2-aryl-8- oksodihydropurinderivater som aktiv bestanddel NO20030474L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000230209 2000-07-31
PCT/JP2001/006363 WO2002010167A1 (fr) 2000-07-31 2001-07-24 Medicaments contre la demence contenant des derives de 2-aryl-8-oxodihydropurine comme ingredient actif

Publications (2)

Publication Number Publication Date
NO20030474D0 NO20030474D0 (no) 2003-01-30
NO20030474L true NO20030474L (no) 2003-03-27

Family

ID=18723200

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030474A NO20030474L (no) 2000-07-31 2003-01-30 Legemiddel mot demens inneholdende 2-aryl-8- oksodihydropurinderivater som aktiv bestanddel

Country Status (19)

Country Link
US (1) US6962921B2 (fr)
EP (1) EP1306378A4 (fr)
KR (1) KR100829297B1 (fr)
CN (1) CN1247578C (fr)
AU (1) AU7278701A (fr)
BR (1) BR0112881A (fr)
CA (1) CA2416706C (fr)
CZ (1) CZ2003234A3 (fr)
HK (1) HK1054231A1 (fr)
HU (1) HUP0303714A3 (fr)
IL (1) IL154049A0 (fr)
MX (1) MXPA03000861A (fr)
NO (1) NO20030474L (fr)
NZ (1) NZ523812A (fr)
PL (1) PL363870A1 (fr)
RU (1) RU2277096C2 (fr)
SK (1) SK1292003A3 (fr)
WO (1) WO2002010167A1 (fr)
ZA (1) ZA200300549B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7760101B2 (en) * 2008-06-20 2010-07-20 Kimberly-Clark Worldwide, Inc. Method of reducing sensor corrosion in absorbent articles
US8735406B2 (en) * 2009-09-09 2014-05-27 Dainippon Sumitomo Pharma Co., Ltd. 8-oxodihydropurine derivative
WO2012168697A1 (fr) 2011-06-06 2012-12-13 Imperial Innovations Limited Procédés de prédiction de l'affinité de liaison à tspo d'agents d'imagerie

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453428A (en) * 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
JPH06508836A (ja) * 1991-06-26 1994-10-06 セプラコア，インコーポレーテッド 光学的に純粋なｒ（＋）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物
GB9208492D0 (en) * 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
US5212195A (en) * 1992-05-13 1993-05-18 Syntex (U.S.A.) Inc. Substituted indole antagonists derivatives which are angiotensin II
ES2232871T3 (es) * 1996-07-03 2005-06-01 Sumitomo Pharmaceuticals Company, Limited Nuevos derivados de purina.
ZA9810490B (en) * 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
ATE300947T1 (de) * 1998-12-18 2005-08-15 Scios Inc Behandlung von erkrankungen mit zystenbildung
DE69932449T2 (de) * 1998-12-18 2007-03-15 Scios Inc., Fremont Agonisten und antagonisten von benzodiazepinrezeptoren des peripheren typs
JP3814125B2 (ja) * 1999-06-02 2006-08-23 大日本住友製薬株式会社 ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬

Also Published As

Publication number Publication date
AU7278701A (en) 2002-02-13
BR0112881A (pt) 2003-07-01
US6962921B2 (en) 2005-11-08
EP1306378A1 (fr) 2003-05-02
CN1466587A (zh) 2004-01-07
US20030166667A1 (en) 2003-09-04
WO2002010167A1 (fr) 2002-02-07
SK1292003A3 (en) 2003-08-05
PL363870A1 (en) 2004-11-29
CZ2003234A3 (cs) 2003-05-14
CA2416706A1 (fr) 2002-02-07
MXPA03000861A (es) 2004-04-05
KR100829297B1 (ko) 2008-05-13
HUP0303714A2 (hu) 2004-03-01
RU2277096C2 (ru) 2006-05-27
NZ523812A (en) 2004-07-30
ZA200300549B (en) 2003-08-19
EP1306378A4 (fr) 2005-02-09
IL154049A0 (en) 2003-07-31
CN1247578C (zh) 2006-03-29
HUP0303714A3 (en) 2007-03-28
NO20030474D0 (no) 2003-01-30
CA2416706C (fr) 2009-04-07
KR20030019634A (ko) 2003-03-06
HK1054231A1 (en) 2003-11-21

Similar Documents

Publication Publication Date Title
DZ3227A1 (fr) Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
ITTO20010008A0 (it) Formulazione farmaceutica
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
FR2804025B1 (fr) Compositions pharmaceutiques stabilisees
NO20030627D0 (no) Hydrogel-drevet medikament doseringsform
NO20042807L (no) Farmasoytiske sammensetninger som innbefatter aktive vitamin D forbindelser
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
EE05376B1 (et) Vesisuspensioonip?hineÁparenteraalneÁravimpreparaatÁjaÁsedaÁsisaldavÁviaal
NO20022970L (no) Hydrogel-drevet medikamentdoseringsform
NO20020976D0 (no) Retarderte, orale, farmasöytiske administreringsformer
EE05063B1 (et) Bensamiididerivaati sisaldav farmatseutiline preparaat
NO20032438L (no) Ortosubstituerte og metasubstituerte bisarylforbindelser, fremgangsmåte forfremstilling derav, deres anvendelse som et medikament samtfarmasöytiske preparater inneholdende forbindelsene
NO20034149L (no) Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
NO20025635L (no) Anvendelse av biguanidderivater til fremstilling av et legemiddel som har en sarhelende virkning
DK1268419T3 (da) Farmaceutisk aktive pyrrolidinderivater som BAX-inhibitorer
DK1624869T3 (da) Doseringsform indeholdende pantoprazol som aktiv bestanddel
NO20032614L (no) Farmasöytisk sammensetning som har forbedret absorberbarhet
IS2258B (is) Setin tríasóló-pýridasín afleiða, lyfjasamsetningar gerðar úr henni
DK1207881T3 (da) Farmaceutisk middel omfattende et benzamidderivat som aktiv bestanddel
FR2802423B1 (fr) Compositions pharmaceutiques
AU2001277738A1 (en) Piperidine derivatives and drugs containing these derivatives as the active ingredient
HUP0303673A3 (en) Piperidine derivatives and pharmaceutical compositions containing these derivatives as the active ingredient
NO20054214D0 (no) Iminoeterderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application